Skip to main content
. 2018 Mar 30;9(24):17117–17132. doi: 10.18632/oncotarget.24965

Figure 2.

Figure 2

(A–C) Radioligand binding assay and immunoreactive fraction determination of 89Zr-DFO-nimotuzumab in EGFR-positive DLD-1 cells. (A) Radioligand binding assay 89Zr-DFO-nimotuzumab showed a KD of 14 ± 2.4 nM with a ~ 577,000 EGFR/cell. (B & C) The immunoreactive fraction of 89Zr-DFO-nimotuzumab was 0.73.